Dr Bae Byuongjun, president of the Korea National Enterprise for Clinical Trials (KoNECT), outlines why Korea stands out in the APAC region as a top clinical trial destination, how clinical trials around COVID-19 treatments are progressing in Korea, the pandemic’s effect on trials for medicines in other indications, and how Korea can lead the way for regulatory science in Asia.
Korea has been, and will continue to be, contributing to the development of robust regulatory science in alignment and harmonization
